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Design: Prospective paired noninferiority observational study.
Setting: Private infertility program.
Patient(s): Forty-three reduced ovarian reserve patients undergoing a PGD-A.
Intervention(s): Both FP and LP stimulations using follicle-stimulating hormone and luteinizing hormone in combination with
gonadotropin-releasing hormone (GnRH) antagonist starting on day 2 of the cycle and 5 days after the ﬁrst oocyte retrieval,
respectively, where GnRH agonist was used for both FP and LP ovulation triggering; a trophectoderm biopsy quantitative
polymerase chain reaction–based PGD-A strategy; and single euploid blastocyst transfers during a subsequent natural cycle.
Main Outcome Measure(s): Primary outcome measure: euploid blastocyst rate per injected metaphase 2 (MII) oocyte; secondary
outcome measures: number of cumulus-oocyte complexes (COCs), MII oocytes, and blastocysts.
Result(s): Patients with an antim€ullerian hormone level of <1.5 ng/mL, antral follicle count of <6 follicles, and/or <5 oocytes
retrieved in a previous cycle were included. No statistically signiﬁcant differences were found in the number of retrieved COCs (5.1
 3.4 vs. 5.7  3.3), MII oocytes (3.4  1.9 vs. 4.1  2.5), or biopsied blastocysts per stimulated cycle (1.2  1.2 vs. 1.4  1.7) from
FP versus LP stimulation, respectively. No differences were observed in the euploid blastocyst rate calculated either per biopsied blas-
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scanner” in your smartphone’s app store or app marketplace.M ultiple major and minor waves in follicular devel-opment have been described in wild ungulatesand large domestic species, including cattle, horse,
sheep, and goats, and also in primates (1–8) and in most
animals where high-resolution ultrasonography has been
used for detailed follow-up studies (9). During major waves,
a dominant follicle develops; during minor waves, no selec-
tion occurs. In contrast, the traditional propitious moment
theory suggested that in humans only a single major wave
of follicle development occurs during the intraovulatory
period (10–12), although even early investigations detected
a limited number of nonatretic follicles with steroidogenic
activity in the luteal phase (LP) (13).
In 2003, based on ultrasonographic studies, Baerwald et al.
(14, 15) reported two or three follicular waves during the
intraovulatory period of healthy women. They suggested that
follicles developing during the LP may have the potential to
ovulate in the presence of an luteinizing hormone (LH)
surge, offering new possibilities for ovary stimulation.
However, their theory was received with scepticism (16–19),
and the suggestion has been disregarded for years.
Application of efﬁcient vitriﬁcation techniques for oocyte
and embryo cryopreservation (20, 21), successes in oocyte
maturation (22), and the need for rapid interventions to
preserve fertility in young cancer patients before the onset
of therapy have led to attempts to obtain oocytes during the
LP without (23, 24) and with stimulation (25–30). Although
in vitro development has been observed after in vitro or
in vivo maturation, no data are available regarding the
developmental competence of these oocytes in vivo (31).
Sporadic indirect information has supported the possibil-
ity that oocytes from follicles developing outside the frames
of the propitious moment scheme may be developmentally
fully competent. In 1997, Hwang et al. (32) reported the birth
of a healthy baby by caesarean delivery after oocyte retrieval,
in vitro maturation, and intracytoplasmic sperm injection
(ICSI) in a donation program. High conception rates after
forced intercourse and heteropaternal superfecundation or
superfetation could be explained by a stress-induced LH surge
that may occur at any point of the menstrual cycle and even
during periods of amenorrhea related to pregnancy and lacta-
tion (33–35).
Direct evidence for competent oocytes from a second
follicular wave has also been published. In 2010, Bentov
et al. (36) reported on a pregnancy that occurred afterVOL. 105 NO. 6 / JUNE 2016extended continuous stimulation, from oocytes derived
from the second follicular wave. Similarly, Kuang et al. (37)
reported the birth of healthy twins from a second wave of fol-
licles after continuous stimulation and oocyte collection on
day 20. The high progesterone level had no negative conse-
quence on follicle maturation and oocyte retrieval. A subse-
quent study of 227 patients stimulated after spontaneous
ovulation reported 68 live births and 44 ongoing pregnancies
without any stimulation-related complications, proving the
feasibility of this approach (38). A double-stimulation strat-
egy applied to poor responders was also successful: mild stim-
ulation in the follicular phase (FP) and a second stimulation
after oocyte retrieval resulted in 13 pregnancies out of the
38 patients initially enrolled to the study (39).
Based on the limited available data, LP stimulation does
not cause an elevated rate of abnormalities at birth (40). In
a comparative study performed on a limited number of oocyte
donation programs, Martínez et al. (31) found no differences
between stimulation during the FP and LP in terms of out-
comes, including fertilization, pregnancy, and implantation
rates. A preliminary note of Moffat et al. (41) outlined a
double-stimulation strategy with identical ﬁrst and second
stimulation protocols, resulting in a similar number of oo-
cytes and blastocysts, thus doubling the ﬁnal blastocyst yield.
Our study applied the double-stimulation approach
within a single menstrual cycle (DuoStim) in a cohort of pa-
tients with a reduced ovarian reserve in a preimplantation ge-
netic diagnosis for aneuploidy testing (PGD-A) infertility
program. An identical protocol was used for both the FP
and LP stimulations, and the euploid blastocyst formation
rates per metaphase 2 (MII) injected oocyte were compared
as the primary outcome.MATERIALS AND METHODS
This prospective paired noninferiority observational study
was performed in a routine infertility program of private
IVF clinics between January and September 2015. Written
informed consent was obtained from all patients who were
enrolled. The study was approved by the Institutional Review
Board of the clinic.
To exploit and compare the developmental quality of
retrieved oocytes after FP and LP stimulation, the euploid blas-
tocyst formation rate per MII injected oocyte by ICSI was set as
the primary outcome measure. The secondary outcome1489
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONvariables were the number of retrieved cumulus-oocyte com-
plexes, MII-phase oocytes, and obtained/biopsied blastocysts.
During the study period, consecutive patients with
reduced ovarian reserve—that is, with an antim€ullerian hor-
mone (AMH) level of%1.5 ng/mL, antral follicular count of
%6 follicles, and/or %5 oocytes retrieved in a previous cy-
cle—undergoing a preimplantation genetic diagnosis for
aneuploidy testing (PGD-A) cycle were enrolled in the study
before the ﬁrst stimulation cycle. Both FP and LP stimulations
were performed with recombinant follicle-stimulating hor-
mone (FSH) and gonadotropin-releasing hormone (GnRH)
antagonist treatment. In particular, after the ultrasonographic
basal status of the ovaries had been assessed, the follicular
stimulation was started on day 2 of the menstrual cycle
with a ﬁxed dose of 300 IU of recombinant FSH and 75 IU
of recombinant LH (Gonal-F, Merck-Serono Italy; Puregon,
MSD-Merck; Luveris, Merck-Serono Italy) for 4 days. The
follicular growth was monitored with ultrasound scans and
estradiol and LH assessment ﬁrst on day 5, and then every
2 days. Daily administration of a GnRH antagonist (Cetrotide
0.25mg,Merck-Serono Italy; Orgalutran 0.25mg,MSD-Italy/
Merck) was started when the leading follicle was 13–14mm in
diameter and continued until the day of the trigger of the
ovulation.
When at least two follicles had reached 17–18 mm in
diameter, ovulation was triggered with a single subcutaneous
bolus of buserelin at the dose of 0.5 mL (Suprefact 5.5 mL;
Hoechst Marion Roussel), and oocyte retrieval was performed
after 35 hours. Five days after the ﬁrst oocyte retrieval a sec-
ond gonadotropin stimulation was started with a GnRH
antagonist protocol identical to the ﬁrst one. When at least
two follicles reached 17–18 mm in diameter, the ovulation
was triggered with a single subcutaneous bolus buserelin at
the dose of 0.5 mL and the second oocyte retrieval was per-
formed 35 hours after (Fig. 1A).
Oocyte retrieval, ICSI, and embryo culture procedures
were described in detail elsewhere (42). Brieﬂy, collection of
cumulus-oocyte complexes was performed via transvaginal
ultrasound-guided aspiration at 35 hours after the trigger. Af-
ter 2 to 4 hours of incubation, the in vitro cumulus and corona
radiata cells were removed by hyaluronidase treatment and
pipetting. For insemination, all MII oocytes were subjected
to ICSI using the technique described elsewhere (42). Pre-
sumptive embryos were cultured individually in 25 mL of Ir-
vine continuous single culture medium (CSCM; Irvine
Scientiﬁc Australia). Culture was performed at 37C in 6%
carbon dioxide and 5% oxygen tension with maximum hu-
midity. Fertilization, cleavage, and development to the blas-
tocyst stage were evaluated up to day 7. The blastocyst
morphology was scored as described by Gardner and School-
craft (43). All embryos reaching the expanded stage on day 5,
6, or 7 were vitriﬁed with the Cryotop method (44) after
biopsy.
The blastocyst biopsy and aneuploidy screening were per-
formed as described in detail elsewhere (45). Brieﬂy, a 10–
20 mmhole was opened on the zona pellucida by a diode laser,
and 5 to 10 trophectodermal cells were removed. The samples
were processed and analyzed at Genetyx SRL Laboratories
(Marostica, VI, Italy) by using quantitative real-time polymer-1490ase chain reaction (46). Karyotype prediction was made for
each embryo by a certiﬁed geneticist.
Embryo transfer was planned in the subsequent natural
cycle after the genetic results on the blastocyst chromosomal
status had been obtained. In all patients, single-embryo trans-
fer (SET) was performed. Clinical pregnancy was determined
by ultrasound demonstration of a gestational sac at 7 weeks.
Themiscarriage rate was assessed as the number of pregnancy
losses per clinical pregnancy achieved. Ongoing pregnancy
was deﬁned as the number of pregnancies beyond the 20th
week of gestation.Statistical Evaluation
Continuous data are presented as absolute mean with stan-
dard deviation (SD). Categorical variables are presented as ab-
solute percentage frequency with 95% conﬁdence interval
(CI). Fisher's exact test and paired t test were used to assess
differences between categorical and continuous variables,
respectively.
A power analysis on the primary outcome (euploid blas-
tocyst formation rate) was conducted to evaluate the sample
size to be included in this study. With a paired noninferiority
design and an expected euploidy blastocyst formation rate of
17% per utilized mature egg in the FP stimulation (47), 320
oocytes were required to exclude a difference of 5%with a po-
wer of 80%. Considering a mean number of four MII-phase
oocytes retrieved from each follicular and luteal oocyte
pickup procedure, and a dropout rate of 10%, 50 patients
(400 eggs) were thus planned to complete this study.
RESULTS
The ﬂowchart of the study is shown in Figure 1B. Out of the 51
patients enrolled for this study, six were excluded because of
no response to the stimulation. The nonresponding patients in
the FP stimulation did not undergo LP stimulation. Forty-ﬁve
patients underwent egg retrieval, but two were excluded after
the ﬁrst stimulation cycle because no sperm was available for
ICSI (Fig. 1B). We performed 43 oocyte retrievals (OPU) in
both FP and LP stimulation, respectively. We obtainedMII oo-
cytes in 84 stimulation cycles, 42 for each stimulation
approach (Supplemental Fig. 1, available online).
The average age of the 43 patients was 39.2  3.4 years
(range: 32.0–44.0 years), the average duration of their infer-
tility period was 2.9  1.8 years (range: 1–9 years) and they
already had a mean number of 0.55  1.1 failed IVF cycles
performed (range: 0–4 years) and 0.56 1.0 previous miscar-
riages (range: 0–4 years). The mean FSH, LH, and AMH levels
were 12.3 7.5 IU (5.0–28.2), 5.1 2.1 IU (3.0–9.0), and 0.7
0.8 ng/mL (0.1–1.8), respectively. The mean antral follicle
count registered was 5.2  2.3 (2–9). These parameters are
consistent with a patient population of poor prognosis.
Apart from reduced ovarian reserve, advanced maternal
age was the most important infertility factor (23 patients,
53.5%). In 23.2% (n¼ 10) of the couples included in the study,
a severe oligoasthenoteratozoospermia was also diagnosed
after sperm analysis. Patients with endometriosis (n ¼ 5),
multiple miscarriages (n ¼ 2), tubal factor infertility
(n ¼ 1), and endocrine-ovulatory dysfunctions (n ¼ 2)VOL. 105 NO. 6 / JUNE 2016
FIGURE 1
(A) Dual stimulation protocol. Five days after the ﬁrst oocyte retrieval, luteal phase stimulation was performed with an identical protocol (as
described in Materials and Methods). Each square represents a day of the cycle. (B) Patient ﬂowchart. (C) Number of patients with at least one
euploid blastocyst according to the relative contribution of each stimulation phase. The number of patients who could cumulatively obtain a
euploid blastocyst increased from 18 (41.9%) of 43 to 30 (69.8%) of 43 when including the luteal phase-derived blastocysts. Twelve patients
(27.9%) had euploid blastocysts exclusively after the luteal phase stimulation.
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respectively.
Two attempts of MII oocyte collections were unsuccess-
ful, including one in the ﬁrst and one in the second stimula-
tion cycle. Fertilization was unsuccessful in three patients
after the ﬁrst stimulation cycle and in two after the second
stimulation cycle. No blastocysts were obtained in 11 and 9
patients after the ﬁrst and second stimulation cycles, respec-
tively, including three patients who did not produce any blas-
tocysts after both cycles. Eventually, one or more blastocysts
were obtained in 31 and 33 patients from the ﬁrst and second
stimulation cycles, respectively (Supplemental Fig. 1).
Detailed comparative analysis of the ﬁrst and second
stimulation cycles (Table 1) did not reveal any difference in
the length of stimulation or the mean number of cumulus-
oocyte complexes, MII-phase oocytes retrieved, or fertilized
eggs, as shown by paired t test analysis. Blastulation and
euploid blastocyst rates per number of biopsied blastocysts
or per MII injected oocytes were similar among FP and LP
stimulations (Table 1). Additionally, no differences wereTABLE 1
Data according to follicular and luteal phase stimulation.
Data basis
Stimulation phase
P valueFollicular Luteal
Per patienta
Days of
stimulation
9.6  2.4 (6–14) 10.3  2.5 (8–15) NS
COCs 5.1  3.4 (1–22) 5.7  3.3 (1–17) NS
MII oocytes 3.4  1.9 (0–10) 4.1  2.5 (0–11) NS
Fertilized oocytes 2.3  1.7 (0–6) 3.2  2.3 (0–10) NS
Biopsied
blastocysts
1.2  1.2 (0–5) 1.4  1.7 (0–9) NS
Euploid
blastocysts
0.6  0.8 (0–3) 0.7  0.8 (0–4) NS
Per injected MII oocyte
MII oocytes 142 173
Fertilized oocytes 99 (69.7) 136 (78.6) NS
Biopsied
blastocysts
49 (34.5) 58 (33.5) NS
Euploid
blastocysts
23 (16.2) 26 (15.0) NS
Per biopsied blastocyst
Biopsied
blastocysts
49 58 NS
Day of blastulation
5 19 (38.8) 22 (37.9) NS
6 29 (59.2) 36 (62.0) NS
7 1 (2.0) 0 NS
Blastocyst quality
Excellent 21 (42.8) 26 (44.8) NS
Good 9 (18.4) 10 (17.2) NS
Average 12 (24.5) 12 (20.7) NS
Poor 7 (14.3) 10 (17.2) NS
Aneuploidy
Euploid 23 (46.9) 26 (44.8) NS
Single/double
aneuploid
18 (37.1) 25 (43.2) NS
Complex
aneuploid
8 (16.0) 7 (12.0) NS
Note: Data are presented as number (%) unless otherwise indicated. Paired Student's t test
was used to compare continuous variables, and Fisher's exact test for categorical ones.
COC ¼ cumulus-oocyte complex; MII ¼ metaphase 2; NS ¼ not statistically signiﬁcant.
a Data are presented as mean  standard deviation (range).
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blastocysts, or in the percentage of blastocysts reaching full
expansion on days 5, 6, and 7 in the two groups, respectively
(Table 1).
Aneuploidy data were also consistent between blastocysts
obtained after FP and LP stimulation, with also similar rates of
single/double and complex aneuploidies obtained in the two
different stimulation phases (Table 1). Eighteen and 23 pa-
tients produced at least one euploid blastocyst after the FP
and LP stimulations, respectively (Fig. 1C; Supplemental
Fig. 1). In 12 patients, euploid blastocysts were obtained
only in the LP (Fig. 1C, Supplemental Fig. 1). Accordingly,
the second stimulation in the LP increased the rate of patients
with at least one possible euploid SET from 18 (41.9%) of 43 (a
rate generally observed in matched poor-prognosis patients at
our center) to 30 (69.8%) of 43 (Fig. 1C, Supplemental Fig. 1).
In 12 (27.9%) of 43 patients more than a single euploid blas-
tocyst was obtained after FP and/or LP stimulation cycles
(Supplemental Fig. 1).Preliminary Clinical Outcomes
At the time of writing, 15 euploid blastocysts had been indi-
vidually transferred during a single cryopreserved replace-
ment cycle. Seven and eight embryos were derived from FP
and LP stimulation, respectively. Five ongoing pregnancies
(71.4%) were obtained with the transfer of blastocysts from
FP stimulation and ﬁve (62.5%) with embryos obtained after
LP stimulation (Table 2). In the latter only LP euploid blasto-
cysts were available, thus conﬁrming the signiﬁcant contri-
bution of LP stimulation to the pregnancy rate on a per
menstrual cycle basis.
DISCUSSION
All infertility treatments aim to obtain a healthy baby—or
establish the chance to have a healthy baby in the future—
with the least possible physical and psychological distress,
including shortening the length of required treatments.
Time is important factor for all patients, but it is crucial for
those with a foreseeable rapid loss/decrease of fertility,
including a malignancy that requires gonadotoxic treatment
or removal of gonads or in poor-prognosis patients. Although
in the latter group the time frame is less constrained, reducingTABLE 2
Preliminary clinical outcomes according to follicular or luteal phase
stimulation.
Outcome
Stimulation phase
TotalFollicular Luteal
No. of SET 7 8 15
No. of clinical
pregnancies (%)
6 (85.7) 6 (75.0) 12 (80.0)
No. of miscarriages (%) 1 (16.7) 1 (16.7) 2 (16.7)
No. of ongoing
pregnancies (%)
5 (71.4) 5 (62.5) 10 (66.7)
Note: SET, single-embryo transfers.
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to obtain an appropriate number of oocytes and subsequently
transfer-quality embryos is a most desirable but very
demanding goal. The incidence of poor responders in a
routine infertility program is estimated to be between 9%
and 24%, with a slight increase in the past decade (48).
Although various stimulation protocols and alternative
approaches have been suggested, a consensus seems to form
only for a few, including the application of GnRH antagonists
and long-acting gonadotropins (48); however, an individual
determination of the gonadotropin dose is strongly advised
(49). In general, to obtain success in poor-responding patient
is one of the most challenging tasks in assisted reproduction.
Our present approach to achieve advancement in this
ﬁeld was based on the following principles. The correlation
between the number of obtained MII oocytes and the number
of blastocysts developing from them may not be linear, and
considerable individual variations may occur. Nevertheless,
with the currently used stimulation treatments more oocytes
mean a better chance to obtain transfer-quality blastocysts;
and the higher the blastocyst number is, the better the chance
to ﬁnd euploid, developmentally fully competent ones (48,
49). The intrinsic handicap of poor responders restricts the
number of retrievable oocytes. Accordingly, any new
approach resulting in a signiﬁcant increase in the number
of retrieved oocytes during a speciﬁc time frame (a single
menstrual cycle) would be a considerable achievement.
Based on some recent ﬁndings about the feasibility of LP
stimulation (24–29, 31), we tested double (i.e., FP and LP)
stimulation in the same menstrual cycle for poor responders
in a routine infertility program.
Our results proved that double stimulation (DuoStim) is
successful for this cohort of patients, resulting in a similar
number of MII phase oocytes after both FP and LP stimula-
tion. The in vitro developmental competence to blastocyst
stage was also similar, and with PGD-A no statistically signif-
icant difference in the proportion of euploid blastocysts
derived from the two stimulation phases was found. These re-
sults conﬁrm the feasibility of double-stimulation in a single
menstrual cycle for poor responders.
Thus far, only one study has been published about Duo-
Stim also for poor responder patients. Kuang et al. (39) re-
ported a higher number of MII-phase oocytes and fertilized
and cleaved embryos after LP versus FP stimulation, but no
difference was found between the high-quality embryo and
cryopreserved embryo numbers. Pregnancies were achieved
from both FP and LP stimulation, but the limited numbers
did not allow a statistical comparison. A remarkable differ-
ence between the work of Kuang et al. and our approach
was that we used identical protocols for both the FP and LP
stimulations. Our results regarding the efﬁciency of oocyte
retrieval, in vitro embryo development, and the aneuploidy
rate justify this simpliﬁed approach, although for any ﬁnal
conclusions, the pregnancy, birth and take-home baby rates,
as well as detection of perinatal complications and post-
partum anomalies will be indispensable (this work is in prog-
ress). For the latter, as already mentioned, promising data
were published by Chen et al. (40), who did not ﬁnd an
elevated rate of birth defects after LP stimulation.VOL. 105 NO. 6 / JUNE 2016DuoStim obviously does not allow fresh embryo transfer.
Cryopreservation of either oocytes or embryos (preferably
blastocysts) is indispensable. With the introduction of a highly
effective cryopreservation protocol for both human oocytes
and blastocysts, the problemwith logistics has been eliminated
(50–53). Blastocyst biopsy is also the most efﬁcient approach
to select euploid embryos for transfer; by application of the
proper embryo culture, biopsy, and vitriﬁcation techniques,
the overall efﬁciency is not compromised (47, 54).
Possible application areas of the DuoStim approach
include [1] all patients in whom obtaining oocytes is urgent,
including those with malignant diseases or other medical in-
dications, and [2] patients of advanced maternal age and/or
reduced ovarian reserve. Additionally, if further studies prove
that combined FP and LP stimulation increases the cumula-
tive live birth rate, DuoStim together with a freeze-all strategy
may be applied more extensively in the future. This approach
clearly helps to save precious time for these difﬁcult patient
populations, and it also may be more cost-effective, depend-
ing on the center's policy. In our center, for example, the sec-
ond oocyte retrieval was free of charge, and a signiﬁcant
reduction in the PGD-A cost was possible by cumulating em-
bryos for a single genetic analysis.
It should also be noted that the discovery of similarities be-
tween humans and certain mammalian species may allow new
models to be developed to study folliculogenesis and ﬁnd
improved models for controlled stimulation. By coincidence,
cattle and horses, in which themost extensive knowledge about
folliculogenesis and ovulation induction has been obtained,
seem to be appropriate for the purpose. These species are
monovular and polycyclic, with anatomic/pathologic condi-
tions and ovary size similar to humans, allowing transrectal
and transvaginal ultrasound investigations and serial blood
collection (9, 55). Of the two species, horses seem to be the
better model. In contrast to cattle where one or two major
anovulatory waves occur during the menstrual cycle, in mares
andhumansonlyonemajorwavedevelops consistently (56, 57).
In conclusion, a similar number of euploid blastocysts per
MII injected oocyte was obtained after FP and LP stimulation
performed in the same menstrual cycle of patients with
reduced ovarian response, respectively. The addition of LP
stimulation signiﬁcantly increased the ﬁnal transferable blas-
tocyst yield compared with FP stimulation alone. This novel
stimulation strategy increased the number of patients with
available euploid blastocysts within a single menstrual cycle
and, in turn, the ﬁnal clinical outcomes. This strategy may be
applied in other situations where obtaining competent oo-
cytes is an urgent task.
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SUPPLEMENTAL FIGURE 1
Graphic representation of the 43 patients included in both follicular and luteal phase stimulation. Each row represents a single patient. Each circle
represents a metaphase 2 (MII) oocyte. The black circles represent MII oocytes that did not reach the blastocyst stage after intracytoplasmic sperm
injection (ICSI). The red circles represent MII oocytes that developed as aneuploid blastocysts after ICSI. The green circles represent MII oocytes that
developed as euploid blastocysts after ICSI. The numbers within circles represent the day of blastocyst development.
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